Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582307 | 0.86 | PDE4B (0.41) | SCN9AFYNPDE4B | |
| SCHEMBL5582146 | 0.85 | JAK3 (0.43) | SCN9APDE4B | |
| SCHEMBL5582243 | 0.85 | IDO1 (0.42) | KITMERTK | |
| SCHEMBL5582253 | 0.83 | KIT (0.49) | KITSCN9A | |
| SCHEMBL5581749 | 0.82 | FYN (0.43) | SCN9AFYN | |
| SCHEMBL5582139 | 0.81 | NPC1 (0.54) | KITPDGFRBPDGFRA | |
| SCHEMBL5581776 | 0.81 | FYN (0.39) | KITPDGFRBPDGFRASCN9AFYN | |
| SCHEMBL5581811 | 0.80 | PDGFRB (0.43) | PDGFRBPDGFRASCN9A | |
| SCHEMBL5582334 | 0.80 | ALDH1A1 (0.40) | KITSCN9A | |
| SCHEMBL5582341 | 0.79 | PDE4D (0.45) | KITPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | KIT 2918/4885PDGFRB 2343/4885PDGFRA 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.